There has been one small-cap biotechnology company riding under the radar of many investors. This company is known as Idera Pharmaceuticals (NASDAQ:IDRA), that is developing treatments for autoimmune diseases and certain genetically defined forms of B-Cell lymphoma. The current share price for Idera is around $3.71 per share with a market cap of $256 Million. We believe that with the current pipeline the company should trade at around $10 per share which would give it a market cap around $650 million. This falls more in line with other biotechnology companies that have compounds in phase 2 clinical trials. Investors should consider the prospects, and take notice of big institutional buyers that have bought some shares of the stock...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|